Skip to main content
RADLY logo

Raia Drogasil S.A. (RADLY) Stock: Price, Forecast & Analyst Target

Raia Drogasil S.A. (RADLY) — price $2.36 (-3.28%), as of the Nov 19, 2026 trading session; market cap $4.13B. Expected results Mar 2, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$2.36 −$0.08 (-3.28%) Market Cap $4.13B

Raia Drogasil S.A. · RADLY · Healthcare · Medical - Pharmaceuticals

Raia Drogasil SA engages in the retail sale of medicine, perfumery, personal care and beauty products, cosmetics and dermocosmetics.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • DMRA · Galecto, Inc. · 50 /100
  • CGEM · Cullinan Therapeutics, Inc. · 51 /100
  • ONC · BeOne Medicines Ltd. · 96 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$2.36
Change on the day-3.28%
52-week range$2.36–$5.34
Market capitalisation$4.13B—
Price / earnings (trailing)19.21
Shares traded on the day1.6K
Beta (volatility vs the S&P 500)0.01

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $2.36, high $5.14, latest $2.36. 4 reported quarters marked, 0 above and 2 below the recorded estimate. $5.14 $2.36 high $5.14 Mar 3, 2026 · Earnings results · reported below the recorded estimate · close $4.621May 6, 2026 · Earnings results · reported below the recorded estimate · close $4.372Aug 4, 2026 · Earnings results · reported in line with the recorded estimate · close $3.903Nov 3, 2026 · Earnings results · reported in line with the recorded estimate · close $2.714 Oct 17, 2025 Nov 19, 2026 · $2.36 $3.68Oct 17, 2025$3.76Oct 31, 2025$4.23Nov 14, 2025$4.48Nov 28, 2025$4.68Dec 12, 2025$4.80Dec 26, 2025$4.60Jan 9, 2026$4.62Jan 23, 2026$5.04Feb 6, 2026$5.14Feb 20, 2026$4.62Mar 6, 2026$4.49Mar 20, 2026$4.25Apr 2, 2026$4.63Apr 17, 2026$4.70May 1, 2026$3.89May 15, 2026$3.84May 29, 2026$3.50Jun 12, 2026$3.68Jun 26, 2026$3.75Jul 10, 2026$3.53Jul 24, 2026$3.90Aug 7, 2026$3.53Aug 21, 2026$3.85Sep 4, 2026$3.82Sep 18, 2026$3.76Oct 2, 2026$3.80Oct 16, 2026$2.76Oct 30, 2026$2.60Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · below the recorded estimate
  • · Earnings results · below the recorded estimate
  • · Earnings results · in line with the recorded estimate
  • · Earnings results · in line with the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for Raia Drogasil (RADLY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Neutral read

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Moderate
Debt/Equity Negative
ROE Moderate
Gross Margin Neutral

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 9, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Raia Drogasil (RADLY), and what does it report?

Short answer

Raia Drogasil SA engages in the retail sale of medicine, perfumery, personal care and beauty products, cosmetics and dermocosmetics. Healthcare / Medical Pharmaceuticals Headquarters: Av. Corifeu de Azevedo Marques, 3097, São Paulo, SP, 05339-900, BR. It employs 73,895 people and is led by Renato Raduan. In Q3 FY2026 it reported revenue of R$11.41B and net income of R$408M. The market values it at $4.13B.

2 · Latest results

What do the latest results show for Raia Drogasil (RADLY)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of R$11.41B. Against analyst estimates the company has EPS beat 3 of the last 8 reports.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$2.08B Nov 3, 2026
Latest report · revenue estimate
$2.43B Nov 3, 2026
Latest report · revenue vs estimate
Below estimate Nov 3, 2026
Latest report · EPS vs estimate
In line Nov 3, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 3, 2026$2.08B$2.43B$0.0500$0.0500
Aug 4, 2026$2.16B$2.32B$0.0500$0.0500
May 6, 2026$2.43B$2.36B$0.0249$0.0334
Mar 3, 2026$2.33B$2.29B$0.0334$0.0398
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026R$11.41BR$408MR$0.24 (diluted)
Q2 FY2026R$11.31BR$434MR$0.25 (diluted)
Q1 FY2026R$10.57BR$159MR$0.09 (diluted)
Q4 FY2025R$12.29BR$310MR$0.18 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Raia Drogasil (RADLY)?

Short answer · as of

The distress and quality screens read Altman Z 3.29 · Piotroski F 7. Trailing ratios: ROE 17.6% · ROA 5.0% · current ratio 1.40 · earnings yield 5.3% · free-cash-flow yield 5.1%.

4 · What to check next?

What should you watch next at Raia Drogasil (RADLY)?

Short answer · as of

The next earnings report is expected on Mar 2, 2027. Current published price targets run low $5.20 · high $5.20 · consensus $5.20 · median $5.20 against a quoted price of $2.36 (as of Nov 19, 2026).

What the records here don't tell us

  • Detailed statement figures are not shown because their conversion to USD has not been verified.
  • No forward revenue or earnings estimate is on file.
  • No insider Form 4 transaction falls inside the window this page reads.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

5 · Score methodology

How is Raia Drogasil scored?

Research dated 2026-09-13.

The core distinction between Raia Drogasil and generic merchandise retailers is its defensive product mix, heavily weighted toward essential medications and health supplies that resist broad economic pullbacks.

Unlike pure online retail platforms, the business relies on an extensive physical logistics footprint across multiple states, tying its valuation directly to the efficiency of its regional distribution centers rather than simple digital customer acquisition. This combined reliance on essential healthcare demand and discretionary beauty segments allows the company to balance steady prescription traffic with higher-margin cosmetic purchases.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
MatsukiyoCocokara & Co. (MSMKF) Named competitor$14.88 Nov 19, 2026$5.85B— Model unavailable
Getinge AB (publ) (GNGBY) Named competitor$27.20 Nov 19, 2026$7.41B— Model unavailable
Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) Named competitor$6.87 Nov 19, 2026$5.09B— Model unavailable
ConvaTec Group Plc (CNVVY) Named competitor$14.09 Nov 19, 2026$6.72B— Model unavailable
DiaSorin S.p.A. (DSRLF) Named competitor$92.00 Nov 19, 2026$4.53B— Model unavailable
Galecto, Inc. (DMRA) Same industry, near in market value$24.30 Nov 19, 2026$1.50B— 5-pillar · not comparable
Cullinan Therapeutics, Inc. (CGEM) Same industry, near in market value$9.07 Nov 19, 2026$589M— 5-pillar · not comparable
BeOne Medicines Ltd. (ONC) Same industry, near in market value$403.60 Nov 18, 2026$46.1B— 5-pillar · not comparable
High Tide Inc. (HITI) Same industry, near in market value$2.29 Nov 19, 2026$204M— 5-pillar · not comparable
LifeMD, Inc. (LFMDP) Same industry, near in market value$18.75 Nov 19, 2026$133M— 5-pillar · not comparable
Satellos Bioscience Inc. Common Stock (MSLE) Same industry, near in market value$5.80 Nov 19, 2026$123M— 5-pillar · not comparable
Pomdoctor Limited (POM) Same industry, near in market value$1.61 Nov 19, 2026$57.9M— 5-pillar · not comparable

The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$5.20 – $5.20
Consensus target
$5.20
Median target
$5.20

Consensus record · Captured .

Measured against a quoted price of $2.36 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held RADLY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported RADLY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Raia Drogasil (RADLY)?

Read these with our analysis →

Common Questions About RADLY (Healthcare)

These answers are editorial: 1 of these 8 answers is drawn from the RADLY research dossier (written Jun 15, 2026 by gpt-4o-mini); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is RADLY a good stock to buy?

Stock Expert AI does not rate RADLY buy, sell or hold. Raia Drogasil S.A. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the RADLY stock price today?

The last price recorded for Raia Drogasil S.A. (RADLY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the RADLY price target?

The analyst consensus price target for Raia Drogasil S.A. (RADLY), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the main risks for RADLY?

Raia Drogasil faces several risks, including potential regulatory changes that could affect the pharmaceutical retail landscape. Additionally, the company contends with intense competition from other pharmacy chains, which could pressure margins.

What are the key factors to evaluate for RADLY?

Evaluate RADLY on fundamentals, analyst consensus, and risk factors. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. Not financial advice.

How frequently does RADLY data refresh on this page?

RADLY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven RADLY's recent stock price performance?

Raia Drogasil S.A. (RADLY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider RADLY overvalued or undervalued right now?

The trailing P/E of Raia Drogasil S.A. (RADLY) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 43 figures on this page — 36 from Financial Modeling Prep (FMP), 4 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • 5. How is Raia Drogasil scored?: Business description; Trailing twelve-month ratio set; Sector / industry (provider taxonomy)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.